In a world with an increasing number of resistant and difficult-to-treat microbes, Pharma Holdings has set off to develop new drugs that are rapid acting and with a low propensity towards resistance development. Our new generation cationic peptide is the result of world-class research in the field of lytic peptides. Further, our compound LTX-109 is derived from a naturally occurring peptide which, together with the low drive towards resistance development, ensures a sustainable way of fighting off infections currently threatening the global health.
In a world with an increasing number of resistant and difficult-to-treat microbes, Pharma Holdings has set off to develop new drugs that are rapid acting and with a low propensity towards resistance development. Our new generation cationic peptide is the result of world-class research in the field of lytic peptides. Further, our compound LTX-109 is derived from a naturally occurring peptide which, together with the low drive towards resistance development, ensures a sustainable way of fighting off infections currently threatening the global health.
Company Information
- Industry
- Company Type
- Privately Held
- Founded
- unknown
- Employee Range
- 1-10
- Revenue Range
- Not available
Location
- Address
- Killengreensgate 2-8 Tromsø
- City
- Oslo
- Region
- Oslo
- Postal Code
- 9008
- Country
- Norway